The prospect of the legalization of marijuana coupled with the excitement surrounding e-cigarettes is spurring innovation and new product development daily.
Unveils VitaCig, Inc. - 100% Owned Subsidiary
Australian vaporizer and e-cigarette maker mCig Inc.'s (OTCQB: MCIG) stock volume soared Feb 6, 2014 with 6,586,756 shares changing hands, more than double its three-month average of 3,067,575 shares. The uptick in activity appeared to be triggered by the Feb. 3 unveiling of VitaCig, Inc., mCig's new product made by its wholly-owned subsidiary.
Taking the same approach applied to the marijuana industry, mCig said it decided to avoid direct competition with the ultra-competitive and highly fragmented nicotine-based eCig industry. Instead, mCig decided to develop a niche product by embracing the potential of eCig technology (the ability to easily vaporize pre-packaged liquids from a pocket-sized device) as a medical delivery device.
In the fall of 2013 the company began quietly working on the new product codenamed: "Vita".
"We incorporated a new subsidiary: VitaCig, Inc. trademarked the name "VitaCig", and developed the "VitaCig" - a nicotine-free eCig that delivers a water-vapor comprised of vitamins, nutrients, and natural flavors," mCig’s CEO Paul Rosenberg said, in a written statement.
As far as mCig is aware, a product comparable to VitaCig does not exist on the market. The company believes that VitaCig could cannibalize both the existing eCig market as well as the e-Hookah markets by providing a superior, enjoyable experience without the nicotine or overly sweet flavors. It believes the product will appeal to a wide market including: Smokers looking to quit, Smokers looking to reduce nicotine consumption, non-smokers, and rehabilitation patients suffering from illnesses.
"With the mCig we developed a brand that immediately disrupted the vaporizer market. With VitaCig we are hoping to disrupt the eCig market," Rosenberg said. "At this stage, it would be foolish to compete head on with the major tobacco companies who are embracing electronic cigarette technology and rolling out nicotine based products," he added.
Find out what could be the best investor’s move when it comes to MCIGS by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Becoming Strong Vaporizer Player
mCig is also making an aggressive foray into the legal marijuana market by recently introducing an herb vaporizer that only retails for $10. On Jan. 10, the company announced that it expected to fulfill all incoming orders within 5-t-10 business days with order lead time declining to 3-to-5 business days by January 21, 2014.
“Today marks an important milestone for our company. In less than six months we have transitioned from a development stage company to launching two iterations of a device that is quickly cementing itself as the most efficient and affordable way to vaporize plant material,” stated mCig, Inc. CEO Paul Rosenberg said, in a written statement.
On Jan. 24, mCig announced that it acquired Vapolution, Inc., an herbal vaporizer company based in Northern California in a non-dilutive transaction that consolidates an industry leader with over $1.3 million (unaudited aggregate revenue since 2010) in sales. The company contends that the acquisition transforms mCig, Inc. into a formidable competitor in two high growth categories: Personal Vaporizers (mCig 2.0, Vapolution PocketVape) and traditional home-use Vaporizers (Vapolution 2.0).
On Feb. 6, MCIG's share price closed at 40 cents, up 5 cents from its close of 35 cents the previous day.
Supplies Equipment for Marijuana Growers
Another marijuana penny stock that's stock volume skyrocketed Feb 6 was Growlife Inc. (OTCBB: PHOT), a Woodland Hills, Calif. holding company. It traded 53,164,244 shares, substantially higher than its three-month average volume of 35,896,118.
On Feb. 6 PHOT shares closed at 34 cents down 5 cents from its closing price of 39 cents the previous day.
Growlife is strongly positioning itself by developing various markets and deploying new products and services for the legal cannabis industry. For example, one of its recently acquired companies makes hydroponic grow containers, which are designed to grow vegetables, herbs, flowers and fruits in any environment. The company appears to be vigorously considering every possible angle and service to capture its piece of the legal cannabis pie.
On Jan. 31, Growlife announced that it had entered into a strategic partnership with RXNB Inc. Growlife entered into an agreement to purchase a 40% equity stake in RXNB Inc. To sell and distribute RXNB proprietary technologies globally and share profits related to technology licensing, subject to the approval of the GrowLife board. GrowLife currently has a 45% ownership interest in OGI, with conditions under which it can gain majority interest.
RXNB is an investment company with holdings in drug formulation, manufacturing, and distribution. The company represents a recent roll-up of several independent companies in the pharmaceutical and nutraceutical market. RXNB has numerous pending patents in the field of THC research and development. RXNB has a portfolio valuation of $110 million dollars and approximately $27.5 million dollars in annual revenue.
Could Become Strong Asset
While this certainly seems like a strong positioning move by Growlife, and it's nice to know that the company it has just acquired a 40% equity share in has revenue of 27.5 million, we don’t have any idea if the company has earned any profits. So again, we must wait for more thorough info before getting too excited about Growlife’s latest moves.
Find out what could be the best investor’s move when it comes to PHOT by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Cannabis Science Inc. (OTCQB: CBIS) stock volume reached Stratospheric heights on Feb 6, with 67,707,024 shares changing hands, nearly three time more than its three-month average of 24,320,653 shares.
Its share volume is being pushed in part by the passage by Congress of the new farm bill this week, which includes a provision legalizing the cultivation and researching of hemp on a limited basis.
Cannabis Science has been lobbying hard for the decriminalization of cannabis research, which is definitely makes it a player that is serious about developing products in a timely and safe fashion.
Lobbying Hard to Make Cannabis Research Possible
The company's government relations team lead, Rick Blake, is working with the U.S. House of Representatives' Cannabis Caucus to ensure that President Obama signs an Executive Order to decriminalize cannabis research. This is one of the bipartisan initiatives of the members of the Cannabis Caucus being facilitated by Cannabis Science. In contrast to many other countries Cannabis Science believes the regulatory landscape of the United States creates unreasonable restrictions on the ability of scientists and physicians to explore promising patient-driven research involving cannabis and cannabinoids.
"Thousands of patients are awaiting the President's action to set cannabis research free," said Director and CEO of Cannabis Science Dorothy Bray, in a Jan. 29 written statement.
The Colorado company that is developing cannabis-based medicines announced on Jan. 16 that it is spearheading an observational clinical research study in 2014 focusing on the use of cannabis and cannabis-based products to treat a variety of medical conditions.
"We will work with full authorization of the regulatory authorities and, most importantly, with the approval from patients," said Cannabis Science President Robert Melamede.
Selling Equipment in Canada and Abroad
On Feb 3, Cannabis Science also announced it would be partnering with MDS, a subsidiary of Medbox, Inc. to sell and distribute equipment to be used in the medical-marijuana industry. Under the terms of the agreement Cannabis Science has a 50/50 gross profit exclusive on any and all MDS equipment sales in Canada and other select markets, according to the release Both Cannabis Science and MDS have multiple opportunities in Canada based on recent developments with medical cannabis in that market. Other countries will follow pursuant to the agreement as Cannabis Science moves forward aggressively in Europe and South America.
CBIS share price closed at 24 cents on Feb. 6, down 5 cents from its closing price of 29 cents the previous day.
Find out what could be the best investor's move when it comes to CBIS by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
Sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals DailyStockMotion.com is often in the know of several large investor awareness campaigns being deployed. Timing is everything when trading Penny Stocks. Gain an Edge by joining the Sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership. Simply sign up for free and start receiving exclusive alerts. Subscribe Here: http://www.sixfigurestockpicks.com/ Disclosure
Sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.